

Code Projet	Titre
2017-08	First line treatment characteristics, clinical practice in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or metastatic Non-Small Cell Lung Cancer
2017-11	Treatment patterns, clinical practice and outcomes for locally advanced (stage III) unresectable non-small cell lung cancer from the ESME Lung database, in real world setting
2018-12	Keytruda® condition of use in advanced non-small cell lung cancer in France - a non-interventional study
2019-09	First line treatment characteristics, clinical practice in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or metastatic Non-Small Cell Lung Cancer
2019-10	Analysis of the effectiveness of crizotinib in patients with advanced ROS1 positive NSCLC from a cohort of the UNICANCER ESME Advanced and Metastatic Lung Cancer platform
2019-18	Retrospective observational study in patients with stage IV Small Cell Lung Cancer to describe patient profile, treatment patterns and outcomes measures in France in real-life setting
2019-24	Keytruda® condition of use in advanced non-small cell lung cancer in France - a non-interventional study
2019-26	Patterns of care and survival of patients with metastatic non-small cell lung cancer (NSCLC)
2019-27	Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic lung cancer
2020-08	Who should be targeted for lung cancer screening: how real life data of ESME database can help?
2020-09	Enrollment of older metastatic lung cancer patients in clinical trials
2020-10	Impact of cannabis in smokers with lung cancer: a multicentric French retrospective study
2020-21	IO-Optimise study part 1 / Real world clinical characteristics, treatment patterns and outcomes in locally advanced or metastatic non-small cell lung cancer patients in France.
2020-22	IO-Optimise study part 2 / Real world clinical characteristics, treatment patterns and outcomes in locally advanced or metastatic non-small cell lung cancer patients in France
2020-23	EGFR Exon 20 Insertion Mutations – Prognostic and Predictive Values in Advanced Non-small Cell Lung Cancer, a RWD Study
2020-24	Advanced/Metastatic Non Small Cell Lung Cancer in older patients: molecular screening and molecular profile
2020-25	Patient outcomes after discontinuation of immunotherapy due to adverse events in patients with lung cancer
2020-26	Lung cancer in patients younger than 45 years: epidemiological, molecular characteristics, prognosis, and therapeutic strategies
2020-29	A retrospective cohort study to characterize patient characteristics and treatment outcomes among patients with advanced or metastatic non-small cell lung cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database
2020-32	MATCHING-ADJUSTED INDIRECT COMPARISON OF ENTRECTINIB VERSUS FRENCH REAL WORLD TREATMENT STRATEGIES IN ROS1-POSITIVE METASTATIC NSCLC PATIENTS
2021-02	Impact of immunotherapy on the risk of second primary cancers in patients treated for metastatic lung cancer
2021-06	Real-world systemic anti-cancer therapy effectiveness in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor Ex20ins (i.e. external control cohort); adjusted comparison between real-world outcomes in the ESME external control cohort and amivantamab outcomes in the CHRYSALIS trial
2021-07	Keytruda® condition of use in advanced non-small cell lung cancer in France - a non-interventional study
2021-08	A retrospective cohort study to characterize patient characteristics and treatment outcomes of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (aNSCLC) who meet the single-arm Phase 2 Study 20170543 criteria within the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME AMLC) Database
2021-17	ESME Lung SNC : Central nervous system metastases incidence, kinetics, prognosis and treatments in lung cancer: a multicenter national observational study based on the ESME cohort
2022-01	Evolution of therapeutic strategies since immunotherapy arrival in France in metastatic non-small cell lung cancer with no sensitizing EGFR mutation or ALK genomic tumor aberrations (EVIMMETA)
2022-05	A retrospective cohort study to characterize patient characteristics and treatment outcomes among patients with KRAS mutated advanced or metastatic non-small cell lung cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database
2022-07	IO-Optimise study / Real world treatment patterns and outcomes in patients treated with nivolumab monotherapy for advanced non-small cell lung cancer in France
2022-19	Retrospective database analyses to describe HER2 testing patterns, patient characteristics, treatment patterns and outcomes in patients with non-small cell lung cancer (HERON database analyses)
2022-20	A retrospective database study to describe profiles prognostic factors and outcomes in patients with locally advanced or metastatic non-small cell lung cancer while on treatment with standard of care osimertinib
2022-21	Keytruda® condition of use in advanced non-small cell lung cancer in France - a non-interventional study
2022-22	Real-world systemic anti-cancer therapy effectiveness in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor Ex20ins (i.e. external control cohort); adjusted comparison between real-world outcomes in the ESME external control cohort and amivantamab outcomes in the CHRYSALIS trial
2022-23	Description des caractéristiques, de la prise en charge et de la survie de la population globale ESME CBP
2022-24	Impact of KRAS mutation subtype on non-small cell lung cancer outcomes: a multicentric French retrospective study
2022-26	Patient characteristics, treatment patterns, and clinical outcomes for locally advanced or metastatic EGFRm NSCLC patients following first- or second-line treatment with osimertinib
2023-03	FIRST-NEC-RWD: first-line treatment of advanced Large-Cell Neuroendocrine Carcinomas (LCNECs) target trial emulation

2023-14	Retrospective database analyses to describe patient characteristics, treatment patterns and outcomes in patients with locally advanced unresectable non-small cell lung cancer
2023-16	Real world study of treatment patterns of ROS1+ treated with crizotinib in ESME database
2023-17	A retrospective cohort study to characterize patient characteristics and treatment outcomes among patients with KRAS mutated advanced or metastatic non-small cell lung cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database
2023-21	Patient characteristics, treatment patterns, and clinical outcomes for locally advanced or metastatic EGFRm NSCLC patients following first- or second-line treatment with osimertinib
2024-02	a Non-Interventional, Retrospective, Observational Cohort Study of Real-World, Front-Line Treatments in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations and Adjusted Comparisons Versus PAPILLON Clinical Trial Patients: NECTAR study
2024-03	SARCPeM - Evaluation de l'efficacité (systémique et cérébrale) et de la tolérance du pembrolizumab en première ligne avec ou sans association à la chimiothérapie dans la prise en charge de carcinomes broncho-pulmonaires non à petites cellules avec contingent sarcomatoïde : étude de vraie vie.
2024-05	Patient characteristics, treatment patterns, and clinical outcomes for locally advanced or metastatic EGFRm NSCLC patients following first- or second-line treatment with osimertinib
2024-11	Clinical characteristics and management of small cell lung cancer long survivors
2024-12	Target trial emulation to evaluate overall survival in the PERSEE trial using real-world data from the ESME lung cohort: a proof-a-concept study
2024-15	Target trial emulation to evaluate overall survival in the PERSEE trial using real-world data from the ESME lung cohort: a proof-a-concept study
2024-19	Immunotherapy for lung cancer patients: focus on long responders and response duration after immunotherapy discontinuation
2024-24	Chemoimmunotherapy in old AMLC patients
2024-27	Real-world treatment patterns of ES-SCLC patients in France and outcomes in 2L using Unicancer EMR data
2024-28	Real-world study of treatment patterns of NSCLC ALK+ treated with ALK TKI in ESME database
2025-01	ESMExFLATIRON: Transportability between FR and US real-world lung cancer databases
2025-02	Développement modèles de maladie utilisant les données de la base ESME poumon
2025-03	Characterization of non-smokers squamous cell lung cancers in comparison to smokers and efficacy of immune checkpoint inhibitors and targeted therapy in terms of real-world progression free survival and overall survival in the large ESME lung cancer database
2025-04	PPI EMULATION: Evaluation par émulation d'essai clinique de l'impact de l'administration concomitante d'inhibiteurs de pompe à proton sur l'efficacité en vie réelle des inhibiteurs de tyrosine kinase ou des inhibiteurs de checkpoint dans le cancer broncho-pulmonaire avancé ou métastatique
2025-11	Theranostic Value of Molecular Alterations in metastatic squamous non-small cell lung cancer
2025-12	Retrospective Analysis of Synchronous Oligometastatic NSCLC Patients Treated with Chemo-Immunotherapy or Immunotherapy Alone
2025-15	Outcomes of ALK-driven NSCLC patients according to first metastatic line and subsequent treatments
2025-16	Second-line efficacy in immunotherapy-pretreated advanced Small-Cell-Lung Cancer
2025-17	Characterization of unresectable stage III ALK-positive NSCLC and response to immune checkpoint inhibitors versus targeted therapy in ESME lung cancer database